Endosomal Toll-like receptors in autoimmunity: Mechanisms for clinical diversity

Therapy

Volumn 6, Issue 3, 2009, Pages 433-442

  Trivedi, Sapna ^a   Greidlinger, Eric L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Dendritic cells; Innate immunity; Interferon regulatory factors; Kidney; Lupus; Toll like receptors

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; DNA; INTERFERON; INTERLEUKIN 12; INTERLEUKIN 6; MESSENGER RNA; MICRORNA; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNITY; B LYMPHOCYTE; CLINICAL FEATURE; CYTOKINE RELEASE; DNA FLANKING REGION; ENDOSOME; HUMAN; IMMUNOPATHOGENESIS; IMMUNOPHENOTYPING; IMMUNOSTIMULATION; INNATE IMMUNITY; INTERFERON PRODUCTION; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; RECEPTOR UPREGULATION; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 69449098465     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/thy.09.2     Document Type: Review

References (75)

1. Barrat FJ, Meeker T, Gregorio J et al.: Nucleic acids of mammalian origin can act as endogenous ligands for Toll-like receptors and may promote systemic lupus erythematosus. J. Exp. Med. 202, 1131-1139 (2005).
2. Savarese E, Steinberg C, Pawar RD et al.: Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum. 58, 1107-1115 (2008).
3. Marshak-Rothstein A: Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 6, 823-835 (2006).
4. Greidinger EL, Zang Y, Jaimes K et al.: A murine model of mixed connective tissue disease induced with U1 small nuclear RNP autoantigen. Arthritis Rheum. 54, 661-669 (2006).
5. Pisitkun P, Deane JA, Difilippantonio MJ, Tarasenko T, Satterthwaite AB, Bolland S: Autoreactive B cell responses to RNA-related antigens due to TLR7 gene duplication. Science 312, 1669-1672 (2006).
6. Rutz M, Metzger J, Gellert T et al.: Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence- and pH-dependent manner. Eur. J. Immunol. 34, 2541-2550 (2004).
7. Kim YM, Brinkmann MM, Paquet ME, Ploegh HL: UNC93B1 delivers nucleotide-sensing toll-like receptors to endolysosomes. Nature 452, 234-238 (2008).
8. Kadowaki N, Ho S, Antonenko S et al.: Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J. Exp. Med. 194, 863-869 (2001).
9. Hubert FX, Voisine C, Louvet C et al.: Differential pattern recognition receptor expression but stereotyped responsiveness in rat spleen dendritic cell subsets. J. Immunol. 177, 1007-1016 (2006).
10. Bengtsson AA, Sturfelt G, Truedsson L et al.: Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies. Lupus 9, 664-671 (2000).
11. Coccia EM, Severa M, Giacomini E et al.: Viral infection and Toll-like receptor agonists induce a differential expression of type I and l interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur. J. Immunol. 34, 796-805 (2004).
12. Gibson SJ, Lindh JM, Riter TR et al.: Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol. 218, 74-86 (2002).
13. Ronnblom L, Pascual V: The innate immune system in SLE: type I interferons and dendritic cells. Lupus 17, 394-399 (2008).
14. Diebold SS, Montoya M, Unger H et al.: Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature 424, 324-328 (2003).
15. Kawai T, Akira S: TLR signaling. Semin. Immunol. 19, 24-32 (2007).
16. Chen ZJ: Ubiquitin signalling in the NF-kB pathway. Nat. Cell Biol. 7, 758-765 (2005).
17. Kawai T, Sato S, Ishii KJ et al.: Interferon-a induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat. Immunol. 5, 1061-1068 (2004).
18. Niewold TB, Hua J, Lehman TJ, Harley JB, Crow MK: High serum IFN-α activity is a heritable risk factor for systemic lupus erythe matosus. Genes Immun. 8, 492-502 (2007).
19. Bennett L, Palucka AK, Arce E et al.: Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J. Exp. Med. 197, 711-723 (2003).
20. Baechler EC, Batliwalla FM, Reed AM et al.: Gene expression profiling in human auto-immunity. Immunol. Rev. 210, 120-137 (2006).
21. Greidinger EL, Zang Y, Martinez L et al.: Differential tissue targeting of autoimmunity manifestations by autoantigen-associated Y RNAs. Arthritis Rheum. 56, 1589-1597 (2007).
22. Christensen SR, Shupe J, Nickerson K, Kashgarian M, Flavell RA, Shlomchik MJ: Toll-like receptor 7 and TLR9 dictate autoantibody specificity and have opposing in?ammatory and regulatory roles in a murine model of lupus. Immunity 25, 417-428 (2006).
23. Deane JA, Pisitkun P, Barrett RS et al.: Control of toll-like receptor 7 expression is essential to restrict autoimmunity and dendritic cell proliferation. Immunity 27, 801-810 (2007).
24. Ma Z, Chen F, Madaio MP, Cohen PL, Eisenberg RA: Modulation of autoimmunity by TLR9 in the chronic graft-vs-host model of systemic lupus erythematosus. J. Immunol. 177, 7444-7450 (2006).
25. Pawar RD, Ramanjaneyulu A, Kulkarni OP, Lech M, Segerer S, Anders HJ: Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J. Am. Soc. Nephrol. 18, 1721-1731 (2007).
26. Hammerbeck DM, Burleson GR, Schuller CJ et al.: Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats. Antiviral Res. 73, 1-11 (2007).
27. Heer AK, Shamshiev A, Donda A et al.: TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses. J. Immunol. 178, 2182-2191 (2007).
28. Le Goffic R, Balloy V, Lagranderie M et al.: Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathog. 2, E53 (2006).
29. Rudd BD, Smit JJ, Flavell RA et al.: Deletion of TLR3 alters the pulmonary immune environment and mucus production during respiratory syncytial virus infection. J. Immunol. 176, 1937-1942 (2006).
30. Schlender J, Hornung V, Finke S et al.: Inhibition of toll-like receptor 7- and 9-mediated α/β interferon production in human plasmacytoid dendritic cells by respiratory syncytial virus and measles virus. J. Virol. 79, 5507-5515 (2005).
31. Sajjan US, Jia Y, Newcomb DC et al.: H. influenzae potentiates airway epithelial cell responses to rhinovirus by increasing ICAM-1 and TLR3 expression. FASEB J. 20, 2121-2123 (2006).
32. Bachar O, Adner M, Uddman R, Cardell LO: Toll-like receptor stimulation induces airway hyper-responsiveness to bradykinin, an effect mediated by JNK and NF-κB signaling pathways. Eur. J. Immunol. 34, 1196-1207 (2004).
33. Greidinger EL, Zang Y, Fernandez I et al.: Tissue targeting of Anti-RNP autoimmunity; effects of T cells and myeloid dendritic cells. Arthritis Rheum. 60(2), 534-542 (2009).
34. Peters W, Cyster JG, Mack M et al.: CCR2-dependent traf?cking of F4/80dim macrophages and CD11cdim/intermediate dendritic cells is crucial for T cell recruitment to lungs infected with Mycobacterium tuberculosis. J. Immunol. 172, 7647-7653 (2004).
35. Demedts IK, Bracke KR, Maes T, Joos GF, Brusselle GG: Different roles for human lung dendritic cell subsets in pulmonary immune defense mechanisms. Am. J. Respir. Cell Mol. Biol. 35, 387-393 (2006).
36. Pawar RD, Patole PS, Ellwart A et al.: Ligands to nucleic acid-specific Toll-like receptors and the onset of lupus nephritis. J. Am. Soc. Nephrol. 17, 3365-3373 (2006).
37. Tomai MA, Imbertson LM, Stanczak TL, Tygrett LT, Waldschmidt TJ: The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes. Cell Immunol. 203, 55-65 (2000).
38. Hartmann G, Krieg AM: Mechanism and function of a newly identified CpG DNA motif in human primary B cells. J. Immunol. 164, 944-953 (2000).
39. Burdt MA, Hoffman RW, Deutscher SL, Wang GS, Johnson JC, Sharp GC: Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum. 42, 899-909 (1999).
40. Anderson P, Phillips K, Stoecklin G, Kedersha N: Post-transcriptional regulation of proin?ammatory proteins. J. Leukoc. Biol. 76, 42-47 (2004).
41. Bekeredjian-Ding IB, Wagner M, Hornung V et al.: Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J. Immunol. 174, 4043-4050 (2005).
42. Herlands RA, Christensen SR, Sweet RA, Hershberg U, Shlomchik MJ: T cell-independent and Toll-like receptor-dependent antigen-driven activation of autoreactive B cells. Immunity 29, 249-260 (2008).
43. Brentano F, Schorr O, Gay RE, Gay S, Kyburz D: RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum. 52, 2656-2665 (2005).
44. Patole PS, Pawar RD, Lech M et al.: Expression and regulation of Toll-like receptors in lupus-like immune complex glomerulonephritis of MRL-Fas(lpr) mice. Nephrol. Dial. Transplant 21, 3062-3073 (2006).
45. Patole PS, Grone HJ, Segerer S et al.: Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor 3 on glomerular mesangial cells and antigen-presenting cells. J. Am. Soc. Nephrol. 16, 1326-1338 (2005).
46. Pawar RD, Patole PS, Zecher D et al.: Toll-like receptor-7 modulates immune complex glomerulonephritis. J. Am. Soc. Nephrol. 17, 141-149 (2006).
47. Benigni A, Caroli C, Longaretti L et al.: Involvement of renal tubular Toll-like receptor 9 in the development of tubulointerstitial injury in systemic lupus. Arthritis Rheum. 56, 1569-1578 (2007).
48. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G: TAM receptors are pleiotropic inhibitors of the innate immune response. Cell 131, 1124-1136 (2007).
49. Dai X, Sayama K, Yamasaki K et al.: SOCS1-negative feedback of STAT1 activation is a key pathway in the dsRNA-induced innate immune response of human keratinocytes. J. Invest. Dermatol. 126, 1574-1581 (2006).
50. Chuang TH, Ulevitch RJ: Triad3A, an E3 ubiquitin-protein ligase regulating Toll-like receptors. Nat. Immunol. 5, 495-502 (2004).
51. Meister G, Tuschl T: Mechanisms of gene silencing by double-stranded RNA. Nature 431, 343-349 (2004).
52. Vasudevan S, Tong Y, Steitz JA: Switching from repression to activation: microRNAs can up-regulate translation. Science 318, 1931-1934 (2007).
53. Lu Z, Liu M, Stribinskis V et al.: MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 27, 4373-4379 (2008).
54. Skriner K, Sommergruber WH, Tremmel V et al.: Anti-A2/RA33 autoantibodies are directed to the RNA binding region of the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. Differential epitope recognition in rheumatoid arthritis, systemic lupus erythematosus, and mixed connective tissue disease. J. Clin. Invest. 100, 127-135 (1997).
55. Jimenez-Boj E, Kedersha N, Tohidast-Akrad M et al.: Autoantibodies to the translational suppressors T cell intracytoplasmic antigen 1 and T cell intracytoplasmic antigen 1-related protein in patients with rheumatic diseases: increased prevalence in systemic lupus erythematosus and systemic sclerosis and correlation with clinical features. Arthritis Rheum. 58, 1226-1236 (2008).
56. Taganov KD, Boldin MP, Chang KJ, Baltimore D: NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl Acad. Sci. USA 103, 12481-12486 (2006).
57. Ishikawa H, Barber GN: STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455, 674-678 (2008).
58. Sadanaga A, Nakashima H, Akahoshi M et al.: Protection against autoimmune nephritis in MyD88-deficient MRL/lpr mice. Arthritis Rheum. 56, 1618-1628 (2007).
59. Nishiya T, DeFranco AL: Ligand-regulated chimeric receptor approach reveals distinctive subcellular localization and signaling properties of the Toll-like receptors. J. Biol. Chem. 279, 19008-19017 (2004).
60. Takaoka A, Wang Z, Choi MK et al.: DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448, 501-505 (2007).
61. Okabe Y, Kawane K, Akira S, Taniguchi T, Nagata S: Toll-like receptor-independent gene induction program activated by mammalian DNA escaped from apoptotic DNA degradation. J. Exp. Med. 202, 1333-1339 (2005).
62. Kato H, Takeuchi O, Sato S et al.: Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441, 101-105 (2006).
63. Kawai T, Takahashi K, Sato S et al.: IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 6, 981-988 (2005).
64. Honda K, Yanai H, Negishi H et al.: IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434, 772-777 (2005).
65. Honda K, Yanai H, Mizutani T et al.: Role of a transductional-transcriptional processor complex involving MyD88 and IRF-7 in Toll-like receptor signaling. Proc. Natl Acad. Sci. USA 101, 15416-15421 (2004).
66. Schoenemeyer A, Barnes BJ, Mancl ME et al.: The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling. J. Biol. Chem. 280, 17005-17012 (2005).
67. Reily MM, Pantoja C, Hu X, Chinenov Y, Rogatsky I: The GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression. EMBO J. 25, 108-117 (2006).
68. McCoy CE, Carpenter S, Palsson-McDermott EM, Gearing LJ, O'Neill LA: Glucocorticoids inhibit IRF3 phosphorylation in response to Toll-like receptor-3 and -4 by targeting TBK1 activation. J. Biol. Chem. 283, 14277-14285 (2008).
69. Korherr C, Gille H, Schafer R et al.: Identification of proangiogenic genes and pathways by high-throughput functional genomics: TBK1 and the IRF3 pathway. Proc. Natl Acad. Sci. USA 103, 4240-4245 (2006).
70. Chien Y, White MA: Characterization of RalB-Sec5-TBK1 function in human oncogenesis. Methods Enzymol. 438, 321-329 (2008).
71. Sigurdsson S, Nordmark G, Goring HH et al.: Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am. J. Hum. Genet. 76, 528-537 (2005).
72. Barnes B, Lubyova B, Pitha PM: On the role of IRF in host defense. J. Interferon Cytokine Res. 22, 59-71 (2002).
73. Takaoka A, Yanai H, Kondo S et al.: Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors. Nature 434, 243-249 (2005).
74. Paun A, Reinert JT, Jiang Z et al.: Functional characterization of murine interferon regulatory factor 5 (IR-5) and its role in the innate antiviral response. J. Biol. Chem. 283, 14295-14308 (2008).
75. Graham RR, Kyogoku C, Sigurdsson S et al.: Three functional variants of IFN regulatory factor 5 (IRF5) define risk and protective haplotypes for human lupus. Proc. Natl Acad. Sci. USA 104, 6758-6763 (2007).